Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Breast Cancer

Free Subscription 07.09.2026 1 AJR Am J Roentgenol 1 Ann Oncol 2 Ann Surg Oncol 4 Anticancer Res 1 BMC Cancer 1 Br J Cancer 5 Breast Cancer 1 Breast Cancer (Auckl) 3 Breast Cancer (Dove Med Press) 5 Breast Cancer Res Treat 2 Breast J 1 Cancer 1 Cancer Chemother Pharmacol 1 Clin Cancer Res 1 Eur J Cancer 1 Int J Cancer 1 Int J Radiat Oncol Biol Phys 2 J Clin Oncol 1 J Natl Cancer Inst 3 PLoS One 1 Proc Natl Acad Sci U S A 1 Radiology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. BAHL M
   Artificial Intelligence and the Future of Personalized Breast Cancer Risk Assessment.
   AJR Am J Roentgenol. 2026 Sep 2. doi: 10.2214/AJR.26.35788.
   PubMed        
   
   

   
   Ann Oncol

2. POGGIO F, Generali D
   "Overall survival with abemaciclib in early breast cancer".
   Ann Oncol. 2026 Sep 1:S0923-7534(26)01482-1. doi: 10.1016/j.annonc.2026.
   PubMed        
   
   

   
   Ann Surg Oncol

3. TSENG J, Dimitroff K, Sauder CAM, Chien AJ, et al
   Correction: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial.
   Ann Surg Oncol. 2026 Sep 3. doi: 10.1245/s10434-026-20526.
   PubMed        
   
   
4. LEGALL C, Darrigues L, Sabah J, Hamy AS, et al
   ASO Visual Abstract: Impact of Tumor Size on Neoadjuvant Chemotherapy Outcomes in Breast Cancer.
   Ann Surg Oncol. 2026 Sep 2. doi: 10.1245/s10434-026-20454.
   PubMed        
   
   

   
   Anticancer Res

5. POSCHKE P, Wenkel E, Schulmeyer C, Hack CC, et al
   Breast MRI With Abbreviated Reading Protocol as Additional Evaluation Tool for Suspicious Microcalcifications in a Screening Cohort: Diagnostic Performance and Interreader Agreement.
   Anticancer Res. 2026;46:5067-5079.
   PubMed         Abstract available
   
   
6. HATA C, Hata T, Hosomi K, Kataoka N, et al
   Predictors of Discontinuation of Eribulin Therapy for Metastatic Breast Cancer: A Retrospective Cohort Study.
   Anticancer Res. 2026;46:5031-5043.
   PubMed         Abstract available
   
   
7. YUSA T, Masuda T, Tomiguchi M, Nagayama Y, et al
   A Case of Concurrent Liver Metastases from Colorectal and Breast Cancer Diagnosed Using Percutaneous Tumor Biopsy.
   Anticancer Res. 2026;46:5339-5345.
   PubMed         Abstract available
   
   
8. WANG Y, Jingu K, Takahashi N, Yamamoto T, et al
   Is Tumor Bed Boost Necessary in Young Patients With Margin-negative Invasive Ductal Carcinoma in the Modern Radiotherapy Era?
   Anticancer Res. 2026;46:5229-5238.
   PubMed         Abstract available
   
   

   
   BMC Cancer

9. SEYYAR M, Sanci PC, Dogan A, Biter S, et al
   Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group.
   BMC Cancer. 2026;26:1047.
   PubMed         Abstract available
   
   

   
   Br J Cancer

10. DIBDEN A, Parmar D, Gabe R, Smith RA, et al
    Long-term effectiveness and overdiagnosis in the NHS breast screening programme: a cohort study with up to 33 years of follow-up.
    Br J Cancer. 2026;135:964-971.
    PubMed         Abstract available
    
    

    
    Breast Cancer

11. ALTUNDAG K
    Exercise prehabilitation in breast cancer surgery: are we measuring the right outcomes?
    Breast Cancer. 2026 Sep 3. doi: 10.1007/s12282-026-01912.
    PubMed        
    
    
12. JUNJUN S, Jing Z, Jie P, Jian C, et al
    Correction: Prognostic model based on six PD?1 expression and immune infiltration?associated genes predicts survival in breast cancer.
    Breast Cancer. 2026 Sep 3. doi: 10.1007/s12282-026-01909.
    PubMed        
    
    
13. MIELNICZEK K, Mlak R, Kowalska A, Jozwik K, et al
    Association between preoperative body composition and health-related quality of life in breast cancer patients: a prospective Eastern European study.
    Breast Cancer. 2026 Sep 3. doi: 10.1007/s12282-026-01911.
    PubMed         Abstract available
    
    
14. AOYAMA Y, Ozaki Y, Kuno M, Kizawa R, et al
    Real-world outcomes of datopotamab deruxtecan after trastuzumab deruxtecan in hormone receptor-positive, HER2-negative metastatic breast cancer.
    Breast Cancer. 2026 Sep 2. doi: 10.1007/s12282-026-01908.
    PubMed         Abstract available
    
    
15. JING L, Lun J, Xu J, Jin Z, et al
    Publisher Correction: PTX3 induces the expression of PD-L1 and promotes breast cancer immune escape : Liyuan Jing.
    Breast Cancer. 2026 Sep 1. doi: 10.1007/s12282-026-01910.
    PubMed        
    
    

    
    Breast Cancer (Auckl)

16. MOTALEBI N, Varshoee Tabrizi F, Khalili-Hezarjaribi H
    Characteristics of Breast Cancer Patients in Northeastern Iran: A Retrospective Cohort Study.
    Breast Cancer (Auckl). 2026;20:11782234261481617.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

17. JIANG M, Wang Q, Xu H
    MST1 and CPNE1 Emerge as Candidate Targets in Breast Cancer: Integration of Mendelian Randomization, Multi-omics Validation, and Functional Interrogation.
    Breast Cancer (Dove Med Press). 2026;18:611734.
    PubMed         Abstract available
    
    
18. OZGE E, Gursu RU, Guney B, Han O, et al
    Association of Pretreatment ANR and IronMLR With Pathological Response Following Neoadjuvant Chemotherapy in Breast Cancer.
    Breast Cancer (Dove Med Press). 2026;18:623894.
    PubMed         Abstract available
    
    
19. ZHONG H, Lu D, Zeng Y, Tu X, et al
    Bilateral Primary Breast Cancer: Current Evidence and Future Perspectives.
    Breast Cancer (Dove Med Press). 2026;18:615577.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

20. SAMPLE JW, Johnson S, Hoskin TL, Redaelli M, et al
    Body mass index-associated gut microbial taxa and functional pathways in women with benign and malignant breast disease.
    Breast Cancer Res Treat. 2026;219:4.
    PubMed         Abstract available
    
    
21. TIAN Z, Li H, Deng Y, Yao H, et al
    Efficacy, safety, and biomarker analysis of neoadjuvant camrelizumab plus apatinib as a chemotherapy-free strategy for early-stage triple-negative breast cancer: a phase II study.
    Breast Cancer Res Treat. 2026;219:3.
    PubMed         Abstract available
    
    
22. IJI R, Oba T, Miyazawa R, Kitazawa A, et al
    Low pectoralis major muscle mass predicts the risk of post-surgical bleeding after mastectomy in patients with breast cancer.
    Breast Cancer Res Treat. 2026;219:2.
    PubMed         Abstract available
    
    
23. PODANY EL, Foffano L, Gerratana L, Medford AJ, et al
    Associations of neighborhood deprivation with breast cancer tumor genomics, targeted treatment use, and survival.
    Breast Cancer Res Treat. 2026;219:5.
    PubMed         Abstract available
    
    
24. CHEN Q, Campbell I, Elwood M, Cavadino A, et al
    Oestrogen receptor testing and initiation of adjuvant endocrine therapy in women with ductal carcinoma in situ: a population-based study.
    Breast Cancer Res Treat. 2026;219:6.
    PubMed         Abstract available
    
    

    
    Breast J

25. LIN S, Zhang B, Yu S, Wang C, et al
    Study on the Pathway Mechanism of Social Support and Quality of Life Between Self-Disclosure and Stigma Among Breast Cancer Patients During Recovery.
    Breast J. 2026;2026:e8826025.
    PubMed         Abstract available
    
    
26. MISTRY C, Walton R, Warner-Smith M, Ren K, et al
    Assessing the Effect of Breast Density on Screening Performance in a Population-Based Program.
    Breast J. 2026;2026:e9750357.
    PubMed         Abstract available
    
    

    
    Cancer

27. WILLIAMS AD, Weiss A
    Adjuvant CDK4/6 inhibitors in early-stage breast cancer: Clinical evidence and considerations for risk stratification and treatment selection.
    Cancer. 2026;132:e70587.
    PubMed         Abstract available
    
    

    
    Cancer Chemother Pharmacol

28. LEI M, Li Z, Xiong C, Xie F, et al
    Trastuzumab treatment is associated with ferroptosis-related alterations in HER2-positive breast cancer organoids.
    Cancer Chemother Pharmacol. 2026;96:96.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

29. LLOYD MR, Pegram MD, Wander SA
    Beyond Amplification: Precision Approaches to Targeting HER2.
    Clin Cancer Res. 2026;32:3715-3717.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

30. SCAFETTA R, Troiano R, Guarino A, Gullotta C, et al
    Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2?- metastatic breast cancer treated with CDK4/6 inhibitors.
    Eur J Cancer. 2026;247:117019.
    PubMed         Abstract available
    
    

    
    Int J Cancer

31. ORSINI L, Zhang Y, Czene K, Humphreys K, et al
    Estimation of Subtype-Specific Tumour Growth Rate Distributions and Interval Cancer Proportions in Breast Cancer Using Biology-Inspired Natural History Models.
    Int J Cancer. 2026 Aug 28. doi: 10.1002/ijc.70721.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

32. MURRAY NZ, Sokeye J, Horns JJ, Chipman J, et al
    Use of Hypofractionation Among Underserved Populations Undergoing Radiation Therapy for Cancer: Implications for Policy.
    Int J Radiat Oncol Biol Phys. 2026;126:301-307.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

33. BENDER U, Ronan K, Amir E
    International Breast Cancer Trials and Optimal Sequence of Treatment.
    J Clin Oncol. 2026 Sep 4:JCO2601228. doi: 10.1200/JCO-26-01228.
    PubMed        
    
    
34. SHAH PD, Parikh RB
    Breast Cancer Risk Assessment Has a Data Integration Problem: Can Artificial Intelligence Solve It?
    J Clin Oncol. 2026 Sep 4:JCO2601598. doi: 10.1200/JCO-26-01598.
    PubMed        
    
    

    
    J Natl Cancer Inst

35. PATEL R, Sparano JA
    Racial disparities in breast cancer: looking beyond the recurrence score.
    J Natl Cancer Inst. 2026 Aug 28:djag253. doi: 10.1093.
    PubMed        
    
    

    
    PLoS One

36. HENRY L, Wilson JS, Wilson JJ, Beck ER, et al
    Core components of physical activity interventions in the prevention and management of breast cancer-related lymphoedema (BCRL): A scoping review.
    PLoS One. 2026;21:e0355189.
    PubMed         Abstract available
    
    
37. HOANG DQ, Cao VK, Nguyen TN, Nguyen NS, et al
    LENS: A mammography-specific hybrid CNN-Transformer with lesion-aware evidence modeling.
    PLoS One. 2026;21:e0350720.
    PubMed         Abstract available
    
    
38. CHOWDHURY MH, Islam F, Khan AA, Siddique MA, et al
    Association of MDM2 rs2279744 and rs937282 polymorphisms with breast cancer susceptibility and circulating MDM2 and p53 levels in Bangladeshi women: A case-control study.
    PLoS One. 2026;21:e0350622.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

39. NISHIDA J, Seehawer M, Rojas Jimenez E, Yan P, et al
    Breast cancer prevention by prophylactic Lalba mRNA-LNP vaccination.
    Proc Natl Acad Sci U S A. 2026;123:e2621855123.
    PubMed         Abstract available
    
    

    
    Radiology

40. FU Q, Zeng Y, Chang R, Xu Z, et al
    Performance of Photon-counting CT for Assessing Pretreatment Breast Cancer: Comparison with Mammography, MRI, and (18)F-FDG PET/CT.
    Radiology. 2026;320:e253531.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum